SAN FRANCISCO, Feb. 06, 2017 -- Invuity, Inc. (NASDAQ:IVTY), a leading surgical photonics company, today announced that it will release its 2016 fourth quarter and full year financial results after the market closes on Tuesday, February 14, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on Tuesday, February 14, 2017, to discuss the financial results and other business developments.
Interested parties may access the live call via telephone by dialing 1-877-556-8638 (U.S.) or 1-615-247-0174 (International), Conference ID: 59656880. To listen to the live call via Invuity's website, go to www.invuity.com, in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call in the Events & Presentations section of the website.
About Invuity®
Invuity, Inc. is a medical technology company focused on developing and marketing advanced photonics devices to improve the ability of surgeons to illuminate and visualize the surgical cavity during open minimally invasive and minimal access surgery. The company's patented Intelligent Photonics™ technology enables enhanced surgical precision, efficiency and safety by providing superior visualization. Clinical applications include women’s health, encompassing breast cancer and breast reconstructive surgery, gynecology and thyroid surgery. Additional applications include procedures for electrophysiology, spine, orthopedic, cardiothoracic, and general surgery. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.
CONTACT: Company Contact: Jim Mackaness Chief Financial Officer Invuity, Inc. 415-655-2129 Investors: Mark Klausner Westwicke Partners 443-213-0501 [email protected]


DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Italy Fines Apple €98.6 Million Over App Store Dominance
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 



